Lecture image placeholder

Premium content

Access to this content requires a subscription. You must be a premium user to view this content.

Monthly subscription - $9.99Pay per view - $4.99Access through your institutionLogin with Underline account
Need help?
Contact us
Lecture placeholder background
VIDEO DOI: https://doi.org/10.48448/n4ae-dg38

technical paper

ENDO 2021

March 21, 2021

Live on Underline

Osilodrostat Is an Effective and Well-Tolerated Treatment for Cushing's Disease (CD): Results From a Phase III Study With an Upfront, Randomized, Double-Blind, Placebo-Controlled Phase (LINC 4)

Please log in to leave a comment

Downloads

Transcript English (automatic)

Next from ENDO 2021

Metopirone Treatment in Endogenous Cushing's Syndrome
Results from a Prospective Multicenter, Open-Label, Phase III/IV Study: PROMPT
technical paper

Metopirone Treatment in Endogenous Cushing's Syndrome Results from a Prospective Multicenter, Open-Label, Phase III/IV Study: PROMPT

ENDO 2021

21 March 2021

Similar lecture

Cures 2: Exogenous Approach - Cell (Beta) Replacement Therapy for T1D
technical paper

Cures 2: Exogenous Approach - Cell (Beta) Replacement Therapy for T1D

ENDO 2020

Bernhard J Hering

10 June 2020

Stay up to date with the latest Underline news!

PRESENTATIONS

  • All Lectures
  • For Librarians
  • Resource Center
  • Free Trial
Underline Science, Inc.
1216 Broadway, 2nd Floor, New York, NY 10001, USA

© 2023 Underline - All rights reserved